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Low-grade inflammation plays a role not only in the pathogenesis of major depressive 
disorder (MDD) but probably also in the poor responsiveness to regular antidepressants. 
There are also indications that anti-inflammatory agents improve the outcomes of 
antidepressants.
Aim: To study whether the presence of low-grade inflammation predicts the outcome of 
antidepressants, anti-inflammatory agents, or combinations thereof.
Methods: We carried out a systematic review of the literature on the prediction capability 
of the serum levels of inflammatory compounds and/or the inflammatory state of 
circulating leukocytes for the outcome of antidepressant/anti-inflammatory treatment in 
MDD. We compared outcomes of the review with original data (collected in two limited 
trials carried out in the EU project MOODINFLAME) on the prediction capability of the 
inflammatory state of monocytes (as measured by inflammatory gene expression) for the 
outcome of venlafaxine, imipramine, or sertraline treatment, the latter with and without 
celecoxib added.
Results: Collectively, the literature and original data showed that: 1) raised serum 
levels of pro-inflammatory compounds (in particular of CRP/IL-6) characterize an 
inflammatory form of MDD with poor responsiveness to predominately serotonergic 
agents, but a better responsiveness to antidepressant regimens with a) (add-on) 
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noradrenergic, dopaminergic, or glutamatergic action or b) (add-on) anti-inflammatory 
agents such as infliximab, minocycline, or eicosapentaenoic acid, showing—next 
to anti-inflammatory—dopaminergic or lipid corrective action; 2) these successful 
anti-inflammatory (add-on) agents, when used in patients with low serum levels of 
CRP/IL-6, decreased response rates in comparison to placebo. Add-on aspirin, in 
contrast, improved responsiveness in such “non-inflammatory” patients; 3) patients 
with increased inflammatory gene expression in circulating leukocytes had a poor 
responsiveness to serotonergic/noradrenergic agents.
Conclusions: The presence of inflammation in patients with MDD heralds a poor 
outcome of first-line antidepressant therapies. Immediate step-ups to dopaminergic 
or glutamatergic regimens or to (add-on) anti-inflammatory agents are most likely 
indicated. However, at present, insufficient data exist to design protocols with reliable 
inflammation parameter cutoff points to guide such therapies, the more since detrimental 
outcomes are possible of anti-inflammatory agents in “non-inflamed” patients.
Keywords: major depression, inflammation, antidepressant therapy, anti-inflammatory therapy, therapy prediction
INTRODUCTION
It is well accepted that immune dysregulation plays an 
important role in the pathogenesis of at least a proportion 
of patients with major depressive disorder (MDD) (1–16). 
Genetic defects and/or polymorphisms, childhood trauma, 
and chronic stress are all capable of eliciting such immune 
dysregulations (17–19). In the last decades, special interest 
has been raised for the role of low-grade inflammation in 
the immune system dysregulation of MDD. Low-grade 
inflammation is characterized by an increase in the level of 
circulating pro-inflammatory compounds, such as acute phase 
proteins [e.g., C-reactive protein (CRP)] and cytokines [e.g., 
interleukin (IL)-6], and/or by a pro-inflammatory activity of 
circulating or tissue resident immune cells (20–23).
A wide range of medications is currently available 
for the treatment of MDD. First-line agents are the well-
known serotonin reuptake inhibitors (SSRIs; e.g., sertraline, 
escitalopram, or citalopram), which show a predominantly 
serotonergic action (24). First-line agents are also the 
serotonin-noradrenaline reuptake inhibitors (SNRIs), which 
show a predominantly serotonergic action at low doses and 
a combined serotonergic–noradrenergic action at moderate 
to high doses (25). Tricyclic antidepressants (TCAs) show 
a similar mechanism of action as SNRIs regarding the dual 
serotonergic-noradrenergic action, but because of more side 
effects, they are actually used as second-line agents. Third-
line agents are drugs with a predominantly noradrenergic/
dopaminergic action, such as mirtazapine or bupropion, or 
agents with other mechanisms of action, such as ketamine 
[i.e., an N-methyl-d-aspartate (NMDA) receptor antagonist, 
elevating glutamate levels]. Despite this wide range of 
medications, response rates to treatment are still insufficient, 
with about half of the patients not responding adequately to an 
installed treatment (26, 27).
Since most of the antidepressant drugs have—next to 
their neurotransmission modulatory effects—also immune 
modulating capacities (28, 29), it is thought that the 
inflammatory state of patients might play a role in non-
responsiveness. To enforce the mood-regulating effects of 
antidepressants, and being aware of the notion that low-
grade inflammation plays a role, various studies have been 
undertaken to use anti-inflammatory agents as add-ons to 
regular antidepressant therapies. In this way, acetylsalicylic 
acid (i.e., aspirin, a COX1 and COX2 inhibitor), selective 
COX-2 inhibitors (e.g., celecoxib), minocycline (a tetracyclin 
with anti-inflammatory effects), and anti-TNF monoclonal 
antibodies (e.g., infliximab) have been used experimentally 
(30–33). Besides these anti-inflammatory agents, agents such 
as cholesterol-lowering fish oil (eicosapentaenoic acid) and 
anti-oxidative n-acetylcysteine have also been used (33, 34). 
These agents also have anti-inflammatory actions, since both 
the cholesterol metabolism and the anti-oxidative machinery 
are linked to inflammation (35, 36). Though it seems that anti-
inflammatory agents did show limited beneficial effects in 
most of the reported studies (30–34), there is still doubt on 
the real validity of such interventions, particularly due to the 
paucity and preliminary character of the studies, while there is 
also the feeling that such anti-inflammatory agents might only 
work in a proportion of patients.
Collectively, the abovementioned notions lead to the view 
that there is a need for a personalized medicine approach to 
select patients who, in particular, will respond to first-line 
agents and those needing immediate step-up therapies to 
drugs other than the first-line drugs and/or an add-on of a 
first-line agent with an anti-inflammatory agent. In such 
an approach, it is the question whether a pre-existent state 
of enhanced low-grade inflammation (present in around 
one-third of patients) (37) indeed plays a role in non-
responsiveness to antidepressants and whether such a state 
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is capable of predicting the outcome of the abovementioned 
antidepressant therapy regimens.
For this report, we have carried out a systematic review 
searching for the relevant literature on the prediction capability 
of soluble inflammatory compounds/cytokines in serum/plasma/
CSF and/or the inflammatory state of circulating leukocytes for 
the outcome of antidepressant/anti-inflammatory treatments 
in MDD. We combined the outcomes of the systematic review 
with experimental data collected in the EU-MOODINFLAME 
consortium on the prediction capability of the inflammatory 
state of circulating monocytes (as measured by inflammatory 
gene expression). Two EU-MOODINFLAME trials could be 
evaluated, a trial carried out on patients with MDD collected at 
the Rotterdam site and treated in first line with venlafaxine or 
imipramine (38), and a small trial carried out on patients with 
MDD collected at the Munich site and treated with sertraline plus 
add-on celecoxib or placebo.
MATERIALS AND METHODS
Search Strategy for Systematic Review
We conducted a systematic literature search in the PubMed/
MEDLINE and Web of Science databases to identify immune-
inflammatory predictors for treatment response to antidepressants, 
anti-inflammatory agents, and/or their combination with anti-
inflammatory agents (or anti-inflammatory agents alone) in 
MDD from inception (for anti-inflammatory) and from 2008 
(for antidepressant) until August 16, 2018. To find additional 
relevant studies, citation lists of included articles were tracked in 
Google Scholar (39) or citation lists of topic-related reviews and 
meta-analyses were checked. The last author of a significant paper 
concerning celecoxib and an expert in the field (NM) was also 
contacted and asked of awareness of any additional studies.
The following search terms were used: (mdd OR major 
depressive disorder OR depression) AND (inflammation) AND 
(therapy OR treatment OR antidepressant drugs OR sertraline OR 
venlafaxine OR escitalopram OR citalopram OR tricyclic OR ssri 
OR snri) AND (biomarker OR cytokines OR il-6 OR t cells OR nk 
cells OR th17 OR leukocytes OR macrophages OR crp OR genes) 
AND (response OR prediction), (mood disorder OR depression 
OR bipolar) AND (anti-inflammatory OR inflammation) AND 
(therapy OR treatment OR medication OR drugs OR add-on 
OR adjunct OR anti TNF OR infliximab OR CRP OR aspirin 
OR ASA OR acetyl salicylic acid OR minocycline OR omega 3 
fatty acids OR NAC OR acetylcysteine OR cox 2 inhibitor OR 
celecoxib) AND (biomarker OR cytokines OR macrophages OR 
t cells OR NK cells OR leukocytes OR CRP OR genes).
The initial search of 7,047 studies resulted in 174 
relevant studies selected by title. Inclusion criteria for further 
selection were:
 (1) publications written in the English language;
 (2) human clinical trials;
(3) the diagnosis of MDD. Because of the paucity of studies in 
unipolar depression, both unipolar and bipolar depression 
were included for the studies on (add-on) anti-inflammatory 
agents. To make comparisons possible, we indicate in the 
result section (Table 1C, marked with B and C) which 
studies included bipolar depressed patients, and we discuss 
in the Discussion section putative differences stemming 
from this inclusion.
 (4) the absence of severe somatic diseases (especially 
inflammation-related);
 (5) the assessment of immune biomarkers;
 (6) the use of first-line or other antidepressant agents or the 
use of an anti-inflammatory agent added to antidepressant 
treatment or alone;
 (7) the assessment of symptom reduction with standardized 
measure [e.g., Hamilton Rating Scale for Depression 
(HAMD), Montgomery–Asberg Depression Rating Scale 
(MADRS), Beck’s depression inventory (BDI)] and
 (8) the analysis of responder and non-responder subgroups.
By reading the abstracts, methods, and results sections 
and applying the inclusion criteria and by removing 
duplicate records, 36 studies were selected. Further exclusion 
criteria were:
 (1) no predictive information provided;
 (2) use of parameters that are not inflammatory biomarkers in a 
narrower sense [e.g., serotonin and kynurenine metabolites, 
brain-derived neurotrophic factor (BDNF), calcium-binding 
protein B (S100B), macrophage-derived chemokine (MDC), 
platelet-derived growth factor (PDGF), and Eotaxin-1/
CCL11];
 (3) genetic studies were excluded except for leukocyte gene 
expression level studies;
 (4) the use of agents whose anti-inflammatory mechanisms 
are not direct and even questionable (e.g., l-methylfolate, 
pioglitazone, modafinil).
By applying these exclusion criteria, we finally included 24 
reports in the systematic review.
With the purpose of providing a comprehensive presentation, 
we decided to split the remaining studies into studies concerning 
circulating inflammatory compounds/cytokines (n = 19, see 
Tables 1A–C) and gene expression in circulating leukocytes 
(n = 5; see Table 2). For detailed information about the study 
selection, see Figure 1.
Experimental Clinical Studies
Details on the inclusion and exclusion criteria, as well as on the 
clinical instruments and characteristics of patients, have been 
published before (38, 64). In short, in- and outpatients were 
recruited from the Departments of Psychiatry at the Erasmus 
Medical Centre (ErasmusMC) in Rotterdam (The Netherlands) 
and at the University Hospital of the Ludwig Maximilian 
University (LMU) in Munich (Germany). All patients were 
diagnosed according to the Diagnostic and Statistical Manual 
of Mental Disorders, Text Revision (DSM-IV-TR) (65) and 
confirmed by using the Structured Clinical Interview for 
DSM-IV Axis I Disorders (SCID-I) (66). Included were patients 
with a minimum score of 17 (Rotterdam) or 22 (Munich) on 
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the Hamilton Rating Scale for Depression (HAMD, 17-item-
version) (67).
Studies had been approved by the ethics committee of 
the medical faculty at the LMU, Munich (Germany), and the 
medical ethics committee of the ErasmusMC, Rotterdam (the 
Netherlands). The study was conducted in compliance with 
standards of Good Clinical Practice (CGP), assuring that the 
rights, safety, and well-being of patients were protected in 
accordance with the principles that have their origin in the 
Declaration of Helsinki (June 1964, last amendment Fortaleza 
2013). Additionally, the relevant national and European 
regulations were adhered, too. After study procedures 
had  been fully explained, all subjects provided written 
informed consent.
Healthy Controls
Healthy controls (HCs) were recruited from the same 
communities (Rotterdam and Munich). Details on the HC can 
be found in Refs. (64) and (68). In short, the inclusion criteria 
for HC were the absence of major DSM-IV-TR Axis I disorders 
including schizophrenia, psychotic disorders, mood disorders, 
anxiety disorders, or substance-related disorders according to 
DSM-IV criteria; the absence of usage of psychiatric drugs; and 
the absence of severe medical illness. HC had to be in self-
proclaimed good health and free of any obvious medical illness 
for at least 2 weeks prior to the blood withdrawal, including 
acute infections and allergic reactions.
Treatment Protocols
Being both double-blind studies, subjects, investigators, and 
study staff had been blinded to the treatment assignment for the 
duration of the study.
Venlafaxine/Imipramine Study (Rotterdam)
Prior to the start of antidepressants, patients with MDD underwent 
a wash-out period for at least 1 week. The use of benzodiazepines 
was allowed up to a maximum daily dose of 3 mg lorazepam 
or the corresponding equivalent. Subsequently, patients were 
randomly assigned to a 7-week monotherapy with either the 
serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine 
FIGURE 1 | Flow diagram of the systematic research. See materials and methods section for further explanation.
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(mean daily dose 371 mg, range dose of 300–375 mg/day) or 
with the TCA imipramine (mean dose 206 mg, range dose of 
50–450 mg/day). The duration of the treatment trial was 7 weeks 
to ensure that patients treated with imipramine had adequate 
plasma levels for at least 4 weeks. Response to treatment was 
defined as ≥50% reduction of the initial HAM-D score.
Sertraline Plus Placebo/Celecoxib Study (Munich)
Prior to the start of treatment, patients with MDD underwent 
a washout period for 3 days. The use of lorazepam or zopiclon 
was allowed in this period and also during the study, up to a 
maximum daily dose of 3 or 15 mg, respectively. Subsequently, 
patients were randomly assigned in a 1:1 ratio to a 6-week 
therapy with either the selective serotonin reuptake inhibitor 
(SSRI) sertraline plus placebo, or with sertraline plus the 
selective COX-2 inhibitor celecoxib. The dose of sertraline 
was flexible and ranged between 50 and 100 mg/day. A daily 
dose higher than 100 mg was not recommended, but in the 
expectation of more clinical benefit, a daily dose of 150 mg 
sertraline was allowed. The daily dose of celecoxib was 400 mg 
(200 mg in the morning and 200 mg in the evening). Patients 
from the placebo group received two identical capsules 
(morning and evening). As in the Rotterdam cohort, response 
to treatment was defined as ≥50% reduction of the initial 
HAM-D score.
Numbers of Patients With MDD and HC
Only patients and HC with full data regarding the expression 
levels of all key genes for monocyte inflammatory activation could 
be used for the present study. The Rotterdam sample therefore 
consisted of 34 MDD patients and 45 HC. Of the patient group, 
14 patients were treated with venlafaxine and 20 patients were 
treated with imipramine. The Munich sample consisted therefore 
of 35 MDD patients and 42 HC. Of the patient group, 19 patients 
were treated with sertraline plus placebo, and 16 patients were 
treated with sertraline plus celecoxib.
Blood Collection
Blood was collected in sodium-heparin tubes (36 ml) for immune 
cell preparation just prior to treatment. From the heparinized 
blood, peripheral blood mononuclear cell (PBMC) suspensions 
were prepared by low-density gradient centrifugation via Ficoll-
Paque PLUS (GE Healthcare, Uppsala, Sweden) within 8 h to 
avoid erythrophagy-related activation of the monocytes. PBMCs 
were frozen in 10% dimethylsulfoxide and stored in liquid 
nitrogen. This enabled us to test immune cells of patients and 
controls together at a later stage. Tests were done at ErasmusMC.
Monocyte Inflammatory Gene Expression
CD14+ monocytes were isolated from aliquots of the frozen and 
thawed PBMCs by a magnetic cell sorting system (auto MACS 
Pro, Miltenyi Biotec, B.V., Bergisch Gladbach, Germany). The 
average viability was 86.3 ± 10.4 (Trypan blue staining) and 
the purity of monocytes was 95.1 ± 3.0% (flow cytometry). 
RNA was isolated from the purified monocytes using RNA 
easy mini kit according to the manufacturer’s instructions 
(Qiagen, Hilden, Germany). On average, monocytes cell yield 
after isolation was 2.0 ± 1.6 × 106/subject and the quantity of 
RNA in monocytes was 3.2 ± 1.8 μg. One microgram of RNA 
was reverse-transcribed using the cDNA high capacity reverse 
transcription kit (Applied Biosystems, Foster City, CA, USA). 
qPCR was performed using Taqman Arrays, format 48 (Applied 
Biosystems), according to the manufacturer’s protocol and 
validated against the single RT-qPCR method. Per fill port, 
400 ng of cDNA (converted from total RNA) was loaded. PCR 
amplification was performed using an Applied Biosystems 
Prism 7900HT sequence detection system with TaqMan Array 
block. Thermal cycler conditions were 2 min at 50°C, 10 min at 
94.5°C, 30 s at 97°C, and 1 min at 59.7°C for 40 cycles.
Based on several previous studies on mood disorders (21, 64, 
69), we decided to include in our panel the most consistently 
abnormally expressed inflammatory genes in the studies. Therefore, 
relative to the housekeeping gene ABL1, the expression of a total of 
up to 49 genes was determined (also because of the maximum of fill 
ports in the Taqman assay) and expression values were calculated 
using the comparative threshold cycle (CT) method [see, for 
technical details, Refs. (21, 64, 69)]. The mentioned earlier studies 
also carried out a hierarchical clustering of these genes and found 
two main distinct clusters of gene expression. The first cluster is 
found consistently in virtually all of our monocyte inflammatory 
gene expression studies (also besides disease conditions such as 
mood disorders), and this cluster is composed of well-known 
pro-inflammatory cytokines and chemokines and important 
enzymes or transcription factors to produce these compounds. For 
the calculation of the “positivity of this inflammatory compound 
cluster”, we took the expression level of the top 10 genes [the most 
consistently overexpressed genes in all our studies thus far; see Ref. 
(64)] of this cluster into consideration, i.e., IL1β, CCL20, EREG, 
IL6, TNFAIP3, CXCL2, PDE4B, ATF3, PTX3, and IL1A. These 
genes accounted for 70–99% of the inflammatory cluster response. 
For each of the 10 genes, we determined a range of the HC gene 
expression (using the 2−ΔCt values). The range was defined by the 
mean of the values for that gene in HC monocytes ± 1 standard 
deviation (SD). Then, we used this range as a standard of comparison 
for the MDD patients’ gene expression. We decided to refer to a 
patient’s top gene as upregulated, if the patient’s gene expression 
was higher than HC’s mean plus 1×SD, or downregulated when 
it was lower than HC’s mean minus 1×SD. This was done for all 
10 above given genes. Then, we declared the monocyte population 
of a given patient as “pro-inflammatory positive” if 6 of these 10 
top inflammatory genes (or more) were upregulated. These data 
are given in Table 3 in the Results section. Similar calculations/
algorithms for monocyte inflammatory positivity have been used 
by us before (21, 69–71). Further methodological details of the 
calculation can be found in these publications. Original Q-PCR 
data have been uploaded and can be retrieved via the GEO 
repository ref number GSE132315: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE132315
Statistics
Statistical analyses were performed using IBM SPSS v.21 for 
Mac. Continuous sample characteristics are reported as mean 
(± standard deviation). Group comparisons (e.g., MDD vs. HC, 
responders vs. non-responders) were analyzed using analysis of 
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variance (ANOVA) tests for continuous data (e.g., age) and using 
Pearson’s chi-square (χ²) tests for categorical data (e.g., gender). For 
group comparisons of positivity of monocyte gene expression (e.g., 
MDD vs. HC, responders/non-responders vs. HC, responders vs. 
non-responders), Pearson’s chi-square (χ²) tests were applied, too. 
All hypotheses were tested with α ≤ 0.05 (two-sided).
RESULTS
Systematic Review Data on the 
Usefulness of Circulating Serum 
Inflammatory Compounds
Tables 1A, 1B, and 1C show the data of the systematic review 
of the 19 selected articles (see the section Search Strategy 
for Systematic Review) regarding the predictive capability 
of inflammatory state [assessed by serum/plasma immune 
compounds (mainly CRP and cytokines) (only one study used 
CSF)] in patients with MDD for the response rates to various 
classes of antidepressant drugs and to anti-inflammatory agents 
added to an antidepressant regimen (except for one study, in 
which the anti-inflammatory agent was used as monotherapy) 
(52). For comprehensibility, we have grouped the outcomes in 
Table 1 according to the regimen used.
Table 1A shows that, in three out of three studies (40–
42), antidepressants with a predominant serotonergic action 
[i.e., escitalopram (SSRI)] induced a better response in patients 
with low inflammatory markers as compared to patients with 
high inflammatory markers in the same study. On the contrary, 
when inflammatory markers were high, five out of seven of the 
studies (40, 45–48) showed that drugs with a predominant 
serotonergic action (i.e., SSRIs, SNRIs, and TCAs) induced 
reduced response rates as compared to patients with low 
inflammatory markers in the same study. Cutoff points for low 
and high levels were defined for CRP in the reviewed studies 
at 1 mg/L; for IL-6 and TNFα, values depended on the actual 
sensitivity of the assay used in the report. Two studies formed 
an exception. Manoharan et al. (44) did not find any effect of 
pre-selection of the inflammatory state. However, this study 
was special in that treatment duration was of only 6 weeks, and 
patients had a relatively low to moderate depression severity 
(HAMD score ≥ 13). The other study (43) showed the opposite 
message (i.e., an improved response to SSRIs in patients with 
a high inflammatory state as compared to a low inflammatory 
state). This study was special, in that many patients were treated 
with paroxetine (SSRIs), which—apart from its serotonergic 
action—also exerts a considerable dopaminergic action (72).
Taken together, predominantly serotonergic agents showed, 
in general, insufficient response rates in those patients with signs 
of moderate to high inflammation as measured by circulating 
inflammatory compounds.
The review also delivered that, in such conditions of moderate 
to high signs of inflammation, drugs with another mechanism 
of action than primarily serotonergic do show an effect. Using 
nortriptyline, mirtazapine, or ketamine alone, or combinations 
of an SSRI with nortriptyline or bupropion resulted, in 5 out of 5 
studies, in improved responses rates (40, 41, 49–51) as compared 
to the patients with low inflammatory markers (Table 1B).
Similar beneficial effects existed for combinations of 
antidepressant drugs with anti-inflammatory agents. Table 1C 
TABLE 1A | Predominantly serotonergic action: higher response rates in low inflammatory state vs. moderate–high inflammatory state (prior to treatment).
INFLAMMATORY STATE STUDY DRUG INFLAMMATORY TEST RESPONSE
LOW Jha et al., 2017 (40) Escitalopram (SSRI) + Placebo CRP < 1 mg/L Higher response rates compared 
to m–h IS *
Uher et al., 2014a (41) Escitalopram (SSRI) CRP < 1 mg/L Higher response rates compared 
to m–h IS ***
Eller et al., 2008 (42) Escitalopram (SSRI) TNFα Higher response rates compared 
to m–h IS *
MODERATE–HIGH Yoshimura et al., 2013 (43) Paroxetine, Sertraline (SSRI) IL-6 Higher response rates compared 
to low IS *
Manoharan et al., 2016 (44) Fluoxetine (SSRI) IL-6 No associations between 
biomarker values and response 
rates
Jha et al., 2017 (40) Escitalopram (SSRI) + Placebo CRP ≥ 1 mg/L Lower response rate compared 
to low IS *
Chang et al., 2012 (45) Fluoxetine (SSRI), Venlafaxine (SNRI) CRP ≥ 1 mg/L Lower response rate compared 
to low IS *
Haroon et al., 2018 (46) SSRIs, SNRIs, TCA CRP, IL-6, TNFα, sTNF-R2 Lower response rate compared 
to low IS *
Yoshimura et al., 2009 (47) Paroxetine, Sertraline, Fluvoxamine, 
Milnacipran (SSRI, SSNRI)
IL-6 Lower response rate compared 
to low IS *
Martinez et al., 2012 (48) Venlafaxine (SNRI) TNFα (CSF) Lower response rate compared 
to low IS *
SSRI, selective serotonin reuptake inhibitors; SNRI, serotonin-norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; TNFα, tumor necrosis factor alpha; IL, interleukin;  
CSF, cerebrospinal fluid; CRP, C-reactive protein; m–h, moderate–high; IS, inflammatory state.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
aImprovement on Montgomery–Asberg Depression Rating Scale (MADRS) score 3 points higher with nortriptyline when CRP ≥ 1 mg/L and 3 points higher with escitalopram when 
CRP < 1 mg/L.
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TABLE 1B | Predominantly noradrenergic, predominantly dopaminergic, and glutamatergic action: higher response rates in moderate–high inflammatory state vs. low 
inflammatory state (prior to treatment).
INFLAMMATORY STATE STUDY DRUG INFLAMMATORY TEST RESPONSE
LOW Jha et al., 2017 (40) Escitalopram (SSRI) + Bupropion (NDRI) CRP < 1 mg/L Lower response rate compared to 
m–h IS *
MODERATE–HIGH Jha et al.,2 017 (40) Escitalopram (SSRI) + Bupropion (NDRI) CRP ≥ 1 mg/L Higher response rates compared 
to low IS *
Uher et al., 2014a (41) Nortriptyline (TCA) CRP ≥ 1 mg/L Higher response rates compared to 
low IS ***
Harley et al., 2010 (49) Fluoxetine (SSRI) + Nortriptyline (TCA) CRP ≥ 1 mg/L Higher response rates compared to 
low IS ***
Yang et al., 2015 (50) Ketamine (NMDA Receptor Antagonist) IL-6 Higher response rates compared to 
low IS ***
Gupta et al., 2016 (51) Mirtazapine (NaSSA) TNFα Higher response rates compared 
to low IS *
SSRI, selective serotonin reuptake inhibitors; NDRI, norepinephrine dopamine reuptake inhibitor; TCA, tricyclic antidepressant; NaSSA, noradrenergic and specific serotonergic 
antidepressant; TNFα, tumor necrosis factor alpha; IL, interleukin; CRP, C-reactive protein; m–h, moderate–high; IS, inflammatory state.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
aImprovement on Montgomery–Asberg Depression Rating Scale (MADRS) score 3 points higher with nortriptyline when CRP ≥ 1 mg/L and 3 points higher with escitalopram when 
CRP < 1 mg/L.
TABLE 1C | Anti-inflammatory agents (added to an antidepressant regimen, except for one study): lower response rates in low inflammatory state (prior to treatment) 
versus placebo and higher response rates in moderate–high inflammatory state versus low inflammatory state (prior to treatment).
INFLAMMATORY STATE STUDY DRUG INFLAMMATORY TEST RESPONSE
LOW Rapaport et al., 2016 
(52)
Monotherapy 
eicosapentaenoic acid (EPA)
e.g., IL-1ra, hs-CRP Lower response rate compared 
to placebo of low inflammatory 
state *
Raison et al., 2013b (53) Infliximab (anti-TNFα) CRP ≤ 5mg/L Lower response rate compared 
to placebo of low inflammatory 
state **
Savitz et al., 2018c (54) Minocycline IL-6 Lower response rate compared 
to placebo of low inflammatory 
state d
Savitz et al., 2018c (54) Aspirin (NSAID) IL-6 Higher response rates compared 
to m–h IS d
MODERATE–HIGH Rapaport et al., 2016 
(52)
Monotherapy 
eicosapentaenoic acid (EPA)
e.g., IL-1ra, hs-CRP Higher response rates compared 
to low IS *
Raison et al., 2013b (53) Infliximab (anti-TNFα) CRP > 5mg/L, TNFα, sTNFR I and II Higher response rates compared 
to low IS **
Savitz et al., 2018c (54) Minocycline IL-6 Higher response rates compared 
to low IS **d
Husain et al., 2017 (55) Minocycline CRP > 5 mg/L Higher response rates compared 
to low IS
Porcu et al., 2018c (56) N-acetylcysteine CRP > 5 mg/L Higher response rates compared 
to low IS *
Hasebe et al., 2017 (57) N-acetylcysteine IL-6 No associations between 
biomarker values and response rates
Panizzutti et al., 2018c (58) N-acetylcysteine CRP, IL-6, TNFα, BDNF, IL-8, IL-10 No associations between 
biomarker values and response 
rates
Savitz et al., 2018c (54) Aspirin (NSAID) CRP No associations between 
biomarker values and response 
rates
Savitz et al., 2018c (54) Aspirin (NSAID) IL-6 Lower response rate compared 
to low IS d
TNFα, tumor necrosis factor alpha; IL, interleukin; CRP, C-reactive protein; m–h, moderate–high; IS, inflammatory state.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, reported effects without significance were not tested for significance but showed a clear descriptive trend and were therefore considered 
noteworthy.
bMixed sample with MDD and bipolar depressed patients, cBipolar depressed sample (type I/II and unspecified), dPersonal communication.
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shows that five out of seven studies (52–56) found a significant 
improvement of an (add-on) anti-inflammatory therapy, when 
patients with high signs were compared to patients with low signs 
of inflammation. The anti-inflammatory agents used in these 
studies were infliximab, minocycline, n-acetylcysteine, and fish 
oil (the latter as monotherapy, and compared to placebo).
It must be mentioned that the study of Savitz et al. (54) only 
noted such improving effect with minocycline; aspirin had no 
such effect in their study. Aspirin did work in their “non-inflamed” 
patients, yet had no effect or even a reduced effect in patients with 
high signs of inflammation, depending on the inflammatory serum 
marker used to determine the state of low-grade inflammation 
(CRP or IL-6, see Table 1C). The study of Savitz was also special 
in that both unipolar and bipolar depressed patients were included.
Table 1C additionally shows that there are also two out of 
three studies (57, 58) that showed that in the case of add-on 
n-acetyl cysteine, it was of no use to stratify the patients in low- 
or high-grade inflammation prior to therapy. Two of the studies 
of add-on n-acetyl cysteine (one showing and one not showing an 
effect of prior determination of the inflammatory state) involved 
both unipolar and bipolar depressed patients.
It was remarkable that when an add-on anti-inflammatory 
agent was given to patients with low signs of inflammation, 
reduced responses were obtained as compared to patients with 
high signs of inflammation and even to placebo (two out of three 
of such studies) (53, 54). Also, when fish oil (an agent with both 
lipid-correcting and anti-inflammatory properties) was given as a 
monotherapy to patients with a low inflammatory state, reduced 
responses were seen as compared to placebo (52) (Table 1C). 
As mentioned above, add-on aspirin did induce an increased 
response in patients with low signs of inflammation in the study 
of Savitz et al. (54).
Taking these literature data together, it is difficult to draw a 
simple conclusion on the usefulness of a prior measurement of 
serum inflammatory markers for the determination of the effect 
of (add-on) anti-inflammatory agents. There is a clear trend 
that (add-on) anti-inflammatory agents, such as infliximab, 
minocycline, and fish oil are effective if inflammatory markers 
are clearly present, but this does not apply to aspirin and 
n-acetylcysteine. However, it is also safe to say that special 
caution must be given when there is an absence of circulating 
inflammatory markers in patients with MDD: the chances are 
high that the use of the effective anti-inflammatory agents (such 
as infliximab, minocycline, and fish oil) in states of moderate–
high inflammation actually has an opposite effect than expected 
in such patients, namely, a reduced responsiveness.
Systematic Review Data on Gene 
Expression in Circulating Leukocytes
Table 2 shows the studies we selected that dealt with the gene 
message for pro-inflammatory cytokine production in the 
circulating leukocyte pool prior to treatment and predictive for 
treatment outcome. We found five relevant articles.
In 2013, Powell et al. (59) described a significantly increased 
baseline expression of TNF in escitalopram non-responders (n = 
21) compared to responders (n = 25) taken from the GENDEP 
study. In the same year, Cattaneo et al. (61) reported on data 
of the GENDEP study and found higher baseline mRNA levels 
for IL1β, macrophage inhibiting factor (MIF), and TNF in 
antidepressant (escitalopram or nortriptyline) non-responders 
compared to responders, the three cytokine expressions together 
explaining 46% of the variance of treatment response.
Belzeaux et al. (63) identified an algorithm of four mRNAs, 
including two cytokine genes (TNF and IL1β, together with PPT1 
and HIST1H1E) to be predictive of the treatment response in MDD. 
However, the weakness of their study was that a whole scale of 
antidepressants was used, while numbers of patients and HC were 
limited (16 vs. 13). Guilloux et al. (60) predicted non-remission 
following escitalopram treatment in MDD with an accuracy of 
79.4% using a 13-gene model including four genes associated with 
immune and inflammatory activation (however, TNF was not 
part of the 13 genes). Mediation of cell proliferation was another 
important function of the remaining genes, but not exclusively. 
In 2016, Cattaneo et al. (62) took the data of the GENDEP study 
further and reported that absolute values of the message for IL1β 
and MIF together could predict non-responsiveness to escitalopram 
or nortriptyline in over 99%. These outcomes were confirmed in an 
independent, naturalistic replication sample.
Taken together, it is clear that non-responsiveness to an 
SSRI or to a TCA (nortriptyline) can likely be predicted by 
determining the expression level of combinations of important 
immune genes (IL1β, MIF, TNF, and CD3) in preparations of 
circulating leukocytes of patients with MDD.
TABLE 2 | The predictive capability of inflammatory state prior to therapy measured by circulating leukocyte gene expression for the response to various antidepressant 
regimens in MDD.
ANTIDEPRESSANT AGENT GENE TRANSCRIPT EFFECT STUDY
Escitalopram (SSRI) TNF Higher levels in non-responders Powell et al., 2013 (59)
Escitalopram (SSRI) 13-gene model, including immune/inflammatory 
genes (CD3D, CD97, IFITM3, and GZMA)
Predicting non-remission with 79.4% accuracy Guilloux et al., 2015 (60)
Escitalopram(SSRI) or Nortriptyline (TCA) IL1β, TNF, and MIF (relative mRNA values) Higher levels in non-responders Cattaneo et al., 2013 (61)
Escitalopram (SSRI) or Nortriptyline (TCA) IL1β and MIF (absolute mRNA values) Algorithm predictive of non-response with 
probability of over 99%
Cattaneo et al., 2016 (62)
Antidepressant treatment, not specified IL1β, TNF, PPT1, and HIST1H1E Algorithm predictive of treatment response Belzeaux et al., 2012 (63)
SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressant; TNF, tumor necrosis factor; IL, interleukin; CD, cluster of differentiation; mRNA, messenger ribonucleic 
acid; PPT1, palmitoyl-protein thioesterase 1; HIST1H1E, histone cluster 1 H1 family member E; MIF, macrophage inhibition factor; IFITM3, interferon-inducible transmembrane 
protein 3; GZMA, granzyme A.
Prediction of Anti-Depressive/Anti-Inflammatory Therapy Response in MDDArteaga-Henriquez et al.
9 July 2019 | Volume 10 | Article 458Frontiers in Psychiatry | www.frontiersin.org
Experimental Data on Inflammation-Related 
Gene Expression in Circulating Monocytes 
as a Predictor of Treatment Response
Prior to treatment, we could test 34 patients with MDD [mean 
age: 52.2 (±9.9) years, 59% females, collected at the ErasmusMC, 
Rotterdam] for inflammatory gene expression in their circulating 
monocytes. As a control group, we tested 45 HC of comparable 
age [mean age: 49.1 (±9.4) years] and gender (44% females). Of 
the 34 patients, 14 were treated with venlafaxine and 20 were 
treated with imipramine. An overall response rate of 11% was 
found in this trial, with 11/34 patients responding to treatment. 
The difference between the response rates for both treatment 
arms were not statistically significant, i.e., a response rate of 36% 
(5/14) for patients treated with venlafaxine and of 30% (6/20) 
for patients treated with imipramine. Vermeiden et al. (38) have 
reported extensively on this study and described that in the 
entire group of patients (n = 85), 45% of the patients responded 
to this first line of drug treatment (measured as 50% HAM-D 
reduction).
The other series of patients involved 35 patients with MDD 
[mean age: 41.4 (±10.8) years, 46.7% females, collected at the 
LMU, Munich] and 42 HC of comparable age [mean age: 37.9 
(±11.9) years] and gender (61.9% females). Of the 35 patients, 
19 were treated with sertraline plus placebo and 16 were treated 
with sertraline plus celecoxib. A high overall response rate was 
found in this trial, i.e., 26/35 (74.3%) of patients responded to 
treatment. The difference between the response rates for both 
treatment arms was not statistically significant, i.e., a response 
rate of 68.4% (13/19) for patients treated with sertraline plus 
placebo and 81.3% (13/16) for patients treated with sertraline 
plus celecoxib.
We determined with an already published algorithm [see the 
Section Monocyte Inflammatory Gene Expression and Ref. (45)] 
the inflammatory state of the monocytes using the top 10 cluster 
1 inflammatory genes (IL1β, CCL20, EREG, IL6, TNFAIP3, 
CXCL2, PDE4B, ATF3, PTX3, and IL1A). We controlled the patient 
monocyte tests with the outcomes of the same tests carried out in 
HC. Table 3 shows that, in each study group, a significant larger 
proportion of patients had—prior to therapy—circulating 
monocytes with a positive inflammatory gene signature as 
compared to the respective HC. Taking all patients from the four 
study groups together, 25 of the 69 (36%) patients with MDD had 
circulating monocytes with a pro-inflammatory gene signature, 
while only 9 of 87 (10%) HC had such monocyte signature (p < 
0.05). This observation is in accord with earlier observations that 
monocytes of part of the patients with MDD show signs of a high 
inflammatory state (21).
For the purpose of this study, we divided the total patient group 
in those with a negative monocyte inflammatory gene score and 
those with a positive score. The data in Table 3 show that in the 
response rates in three out of four patient groups, patients with a 
positive inflammatory gene score had a lower response rate than 
those without a positive score. This, however, did not apply to 
the sertraline plus placebo group, and also significant differences 
were not reached in any of the groups. The phenomenon of better 
responsiveness in “non-inflamed” MDD patients could also be 
seen in the total MDD patient group; patients with a positive 
inflammatory gene score had a lower response rate than patients 
without a positive inflammatory gene score (i.e., 44% vs. 59%); 
however, a statistical significance was not reached in the total 
group of patients.
DISCUSSION
The Predictive Capability of the 
Inflammatory State for Anti-Depressive 
and Anti-Inflammatory Treatment and 
Potential Mechanisms
The data of the systematic review and experimental monocyte 
data, as presented in this study, collectively point in the 
direction that the state of so-called low-grade inflammation 
does play a role in the outcome of antidepressant therapy of 
patients with MDD.
Low-grade inflammation is characterized by an increase in 
the serum level of pro-inflammatory compounds (e.g., CRP, 
IL-1 β, IL-6, and TNF-α) and/or an activation state of circulating 
or tissue resident immune cells, including the brain microglia. 
Both an increase in pro-inflammatory compounds in the blood 
of patients with MDD and a pro-inflammatory activation 
TABLE 3 | Proportions of patients with a positive inflammatory gene signature of circulating monocytes prior to therapy measured in total and by response. 
Predominantly serotonergic agents HC MDD Inflammatory negatives Inflammatory positives
Positive Positive Responders Non-responders Responders Non-responders
Sertraline plus Placebo (SSRI) 5/42 (12%) 7/19 (37%) 8/12 (67%) 4/12 (33%) 5/7 (71%) 2/7 (29%)
Sertraline plus Celecoxib (COX-2 inhibitor) idem 3/16 (19%) 11/13 (85%) 2/13 (15%) 2/3 (67%) 1/3 (33%)
Venlafaxine (SNRI) 2/22 (9%) 6/14 (43%) 3/8 (38%) 5/8 (62%) 2/6 (33%) 4/6 (66%)
Imipramine (TCA) 2/23 (9%) 9/20 (45%) 4/11 (36%) 7/11 (64%) 2/9 (22%) 7/9 (78%)
SUM 9/87 (10%) 25/69 (36%)* 26/44 (59%)* 18/44 (41%)* 11/25 (44%)* 14/25 (56%)*
SSRI, selective serotonin reuptake inhibitors; SNRI, sertraline–noradrenaline reuptake inhibitors; TCA, tricyclic antidepressant; COX-2, cyclooxygenase 2; HC, healthy controls; MDD, 
major depressive disorder.
*p ≤ 0.05 compared to HC.
Positivity was defined by an upregulation of 6 (or more) of the 10 cluster 1 genes.
Original Q-PCR data have been uploaded and can be retrieved via the GEO repository ref number GSE132315: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE132315
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of microglia and/or of myeloid cells in the periphery (i.e., 
monocytes) have been documented in a considerable (≈30–40%) 
proportion of patients with MDD (20, 73, 74). Moreover, imaging 
and histological techniques have shown microglial activation in 
the hippocampus of depressed patients (75).
By producing an array of neurotrophic factors, pro- and 
anti-inflammatory cytokines (e.g., IL-6), as well as axon 
guidance molecules, non-inflammatory activated microglia 
has been implicated both in white matter integrity and in 
the adequate development and function of important stress-
regulating systems in the healthy brain (76, 77). On the contrary, 
inflammatory activated microglia (and/or a transfer of peripheral 
pro-inflammatory cytokines to the brain) is thought to hamper 
the normal development, growth, and synaptic function of 
stress-regulating systems and brain connections important 
for mood regulation, such as the white matter tracts between 
the forebrain and the limbic system. To illustrate this, raised 
serum pro-inflammatory cytokine levels have been associated in 
mood disorder patients with increased activation of threat- and 
anxiety-related neuro-circuits (78), reduced neural responses to 
negative stimuli in frontal brain regions involved in cognitive 
and emotional functions (79), and compromised integrity of 
myelin sheaths in cortico-limbic networks involved in mood 
regulation (80).
Importantly, low-grade inflammation has been shown to 
influence not only brain development and function but also 
neurotransmission, with excellent reviews on the inhibitory 
effects of pro-inflammatory cytokines, such as IL-1β and TNF-
α, on the synaptic availability of monoamines and BDNF, while 
the same cytokines have been shown to increase extracellular 
glutamate, all important molecular determinants in MDD 
pathogenesis and response to treatment (15).
The data from the here presented systematic review on 
circulating inflammatory compounds indicate that patients 
with MDD with an activated inflammatory state (as measured 
by, e.g., moderate to high levels of circulating CRP, IL-6, and/or 
TNF-α) show reduced response rates to antidepressant regimens 
with a primarily serotonergic action (e.g., escitalopram), 
while showing improved response rates to antidepressant 
regimens with a primarily noradrenergic (e.g., nortriptyline), 
dopaminergic (e.g., bupropion, mirtazapine), or glutamatergic 
action (i.e., ketamine).
The systematic review data on the inflammatory 
gene expression in circulating leukocytes confirmed this 
phenomenon, showing that patients with a high gene 
expression level of IL1β, TNF, and/or MIF did not respond 
well to interventions with an SSRI in comparison to MDD 
patients with a low expression of these genes. However, gene 
data in circulating leukocytes disagreed with the data reported 
for circulating inflammatory compounds regarding TCA. 
While the primarily noradrenergic TCA nortriptyline did not 
give a satisfactory response in patients with MDD with a high 
gene expression level in circulating leukocytes (see Table 2), 
nortriptyline did in patients with high levels of circulating 
inflammatory compounds (see Table 1B).
Apparently, inflammatory gene expression in leukocytes 
does not measure the same level of inflammation than the 
measurement of circulating inflammatory compounds in 
serum/plasma; a high inflammatory gene expression might 
typify a state of “stronger/other” inflammation in MDD 
needing a treatment with drugs beyond the serotonergic and 
noradrenergic drugs. In other studies, we have also noted that 
inflammatory gene expression in circulating cells does not 
correlate one to one with the circulating protein gene product 
in serum/plasma (81). We explained this phenomenon by 
assuming that resident cells, such as the endothelial cells and 
resident macrophages in the tissues, also contribute to the level 
of circulating inflammatory compounds.
Although the data of our experiments on inflammatory 
gene expression levels in circulating monocytes (a subset of the 
circulating leukocytes) did not deliver statistically significant 
results, they were, by and large, in agreement with the above-
described findings for the gene expression in all circulating 
leukocytes and showed that patients with “inflammatory” 
monocytes showed reduced response rates to predominantly 
serotonergic drug interventions and patients with “non-
inflammatory” monocytes showed higher response rates to these 
type of agents.
Collectively, we deduce from these data that MDD patients 
with an activated inflammatory state (as measured by moderate 
to high circulating levels of, e.g., CRP, TNF-α, and IL-6, or a 
high gene expression of, e.g., IL1β, TNF, and MIF in circulating 
leukocytes) need more than a monotherapy with a predominantly 
serotonergic agent to improve clinically in a satisfactory way. An 
option then seems to be an immediate step up to agents with also 
a strong dopaminergic or glutamatergic action.
The reason for a better response to dopaminergic or 
glutamatergic drugs in the case of signs of enhanced inflammation 
can only be speculated on. It is possible that these drugs are 
needed because they also have clear anti-inflammatory actions, 
counteracting the detrimental effects of the high inflammatory 
state on the signs and symptoms of depression. There is ample 
evidence that dopamine and ketamine can reduce the production 
of pro-inflammatory cytokines and enhance that of anti-
inflammatory cytokines (82, 83). On the other hand, the pro-
inflammatory state itself may lead to an altered neurotransmitter 
metabolism, necessitating more than a primarily serotonin 
reuptake inhibition, but also an intervention in the dopamine 
or glutamate metabolism. Pro-inflammatory cytokines have 
been reported to activate neuronal mitogen-activated protein 
kinase (MAPK) pathways, increasing monoamine transporter 
expression and activity in general, which leads to an increased pre-
synaptic reuptake of not only serotonin but also other neuroactive 
amines (84, 85). Furthermore, the state of enhanced inflammation 
is thought to lead to an enhanced tryptophan breakdown via the 
kynurenine pathway, resulting in various neuroactive compounds, 
among which NMDA agonists and antagonists, aggravating 
glutamatergic neurotransmitter imbalances (86, 87). This might 
also necessitate more than only a serotonin reuptake inhibition to 
be effective.
A step up to dopaminergic and glutamatergic antidepressants 
was more effective in “inflammatory” MDD patients than in “non-
inflammatory” patients, and a combination of an antidepressant 
with an anti-inflammatory agent increased the response rates in 
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these “inflammatory” patients with MDD as compared to “non-
inflammatory” MDD patients. Though the reviewed literature 
data are scarce, the best prediction results seem to be obtained 
for infliximab (anti-TNF-α agent), minocycline (tetracycline), 
and eicosapentaenoic acid (fish oil). For n-acetylcysteine, the 
inflammatory state did show conjectural prediction effects, 
while for aspirin (acetylsalicylic acid), a reduced response was 
actually seen in “inflammatory” patients as compared to “non-
inflammatory” patients.
The strength or character of the anti-inflammatory agents 
may have played a role in this variation of predictability of 
the state of inflammation for the (add-on) anti-inflammatory 
agents. Both anti-TNF agents and minocycline are in clinical 
practice and are considered stronger anti-inflammatory drugs 
than n-acetylcysteine and aspirin. However, for fish oil, a high 
inflammatory state was also predictive for a better effect in 
MDD patients, while fish oil is considered a relatively weak 
anti-inflammatory agent. Interestingly, fish oil exerts its anti-
inflammatory effects via changing the “bad” pro-inflammatory 
lipid state of individuals (88), and perhaps the high state of 
inflammation in MDD patients is primarily driven by a bad lipid 
profile, which is then best corrected by fish oil.
Also, direct or indirect neurotransmitter effects of the 
anti-inflammatory agents may have played a role in the 
success or failure to predict their improved responsiveness 
in “inflammatory” MDD patients. Interestingly, two of the 
three add-on anti-inflammatory agents (minocycline and 
fish oil) that worked better in “inflammatory” than in “non-
inflammatory” patients possess dopaminergic activities (89, 
90). N-acetylcysteine, of which it is conjectural whether it 
works better as add-on in “inflammatory” than in “non-
inflammatory” MDD patients, influences both dopamine 
and glutamate levels in the brain (91). Add-on aspirin, in 
contrast, had fewer effects in “inflammatory” MDD patients 
as compared to “non-inflammatory” patients; interestingly, 
aspirin has anti-glutamatergic actions (92, 93). These varying 
neuro-modulating actions of anti-inflammatory drugs make 
complex interactions in the neuro-immune network possible, 
inducing varying outcomes of combinations of antidepressants 
and anti-inflammatory agents. Of note also is that three of 
the reviewed studies of add-on anti-inflammatory agents 
had included bipolar depressed patients (54, 56, 58). This 
applies in particular to the study on aspirin (54), in which 
a reducing effect was found in “inflammatory” versus “non-
inflammatory” patients. Intrinsic differences between bipolar 
and unipolar depression, such as differences in the immune 
and the glutamate state (94–98), may have played a role here.
Despite the above-listed uncertainties, it is nevertheless tempting 
to postulate—based on the outcomes of the literature review—
that when MDD patients are “inflammatory”, (add-on) anti-
inflammatory drugs are also an option to improve responsiveness 
and then the best results are probably obtained when anti-
inflammatory agents are potent, influence lipid metabolism, and/or 
influence primarily dopaminergic synaptic transmission.
Regarding the use of (add-on) anti-inflammatory agents, 
another important message emerges from our systematic 
review of the literature. Interestingly, three out of four reports 
(52–54) indicated that “non-inflammatory” MDD patients 
showed a reduced response rate as compared to even placebo to 
the effective (add-on) intervention with an anti-inflammatory 
agent. In other words, the addition of the anti-inflammatory 
drugs effective in “inflammatory” patients was detrimental, 
and the anti-inflammatory drugs inhibited the effect of the 
antidepressants or delayed natural recovery. Such an outcome of 
an anti-inflammatory regimen is counterintuitive, if one assumes 
that inflammation contributes to depressive symptomatology 
(see before). The authors of one of the papers describing this 
phenomenon (53) explain their finding, that perhaps a small 
activation of the inflammatory system is needed for mental 
well-being and that both an extreme low and an extreme high 
activity of the inflammatory response system is disadvantageous 
for mental health. In other words, there would be an optimal 
set point for the inflammatory state of an individual for mental 
health. Downregulating this optimal state with an effective anti-
inflammatory agent would, in such a view, be counterproductive 
and would open the way for the development of depressive 
symptoms.
Another explanation is that there exists a form of MDD that 
is non-immune and characterized by absent serological markers 
of immune activation. As indicated, (add-on) aspirin has a 
beneficial effect in patients and it can be hypothesized that it is 
in particular the neuro-modulating effect (anti-glutamatergic) of 
aspirin that induces this effect.
Based on this literature review, what appears to be the 
best and easiest assay system to measure the inflammatory 
state of MDD patients? The systematic review data on the 
gene expression level of cytokines in circulating leukocytes 
showed that two of the leukocyte gene expression studies 
resulted in very good accuracy rates of prediction of non-
responsiveness, and algorithms could be developed, which 
showed high accuracies from 75% to even a 100% to predict 
non-responsiveness to an SSRI/TCA drug intervention (60, 
62). Apparently, high levels of inflammatory cytokine gene 
message in circulating leukocytes are a precise sign of poor 
(treatment) outcome, and perhaps even better than high levels 
of inflammatory compounds/cytokines in serum/plasma. 
Nevertheless, it is technically less demanding to measure 
inflammatory compounds/cytokines in serum/plasma than 
to perform a gene expression assay in circulating leukocytes. 
Regarding the inflammatory markers best to be measured in 
serum/plasma to determine a raised inflammatory state in 
patients with MDD, it is worthy to note that the most consistent 
effects were found in our literature analysis with circulating 
CRP and/or IL-6 levels. These inflammatory compounds were 
tested in a large proportion of the here reviewed studies on 
serum inflammatory compounds (15/19), and outcomes and 
conclusions were congruent between these studies regarding 
these two inflammation markers.
Circulating TNF-α was measured in only six studies; hence, 
sufficient information on the validity of this parameter is lacking. 
Importantly, one of the studies showed that circulating TNF-α 
levels were not in agreement with the general rule, finding that a 
high TNF-α level was not predictive of a decreased responsiveness 
to an SSRI/SNRI (while a high IL-6 level in the same study was) 
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(43). Other circulating inflammatory compounds (e.g., IL-8, 
IL-10, and IL-1) have also been tested in the here reported 
studies, but in only very few studies, and therefore data cannot 
be reliably evaluated. They nevertheless showed the general trend 
for serum/plasma factors that, in a state of inflammation, more 
than a monotherapy with a predominantly serotonergic agent 
might be needed.
Collectively, it seems that for predicting responsiveness to 
regular antidepressants, the avenue exploring the usefulness of 
serum/plasma CRP and IL-6 determination is the easiest and 
clinically the most feasible and promising approach. High levels 
of CRP/IL-6 would indicate that treatment with a serotonergic 
drug is not effective enough. However, the data reviewed here 
also indicate that the gene expression in circulating leukocytes 
cannot be neglected as a predicting parameter due to the reported 
high levels of accuracy to predict non-responsiveness to SSRI/
SNRI and TCA therapy.
Limitations
In this article, we only focused on inflammation parameters 
as determinants for the outcome of treatment. The various 
other determinants important for treatment outcome have 
recently been reviewed by Perlman et al. (99). The authors 
described not only that inflammation-related determinants are 
important but also that a whole array of genetic, endocrine, 
neuroimaging, sociodemographic, and symptom-based 
predictors turn out to influence outcome. However, due to 
heterogeneous sample sizes, effect sizes, publication biases, 
and methodological disparities across reviews, Perlman 
et al. (99) concluded that they could not accurately assess the 
strength and directionality of the predictors, and the authors 
therefore highlighted the importance of large-scale research 
initiatives and the use of clinically easily accessible biomarkers, 
as well as the need for replication studies of current findings. 
Clearly, we support such view and underscore the notion that 
our review data are also affected by the heterogeneous sample 
sizes, effect sizes, publication biases, and methodological 
disparities and that the data do not yet give a clear-cut picture. 
Also, our own experimental data on monocyte gene expression 
were underpowered and too limited to obtain clear-cut results 
and significances. Thus, clearly more studies are needed 
using standardized add-on anti-inflammatory treatments to 
standardized single antidepressant medications to develop 
a clearer picture of the actual response rates in immune and 
otherwise stratified patients with MDD.
Conclusions
There are excellent recent reviews on the discovered signs of low-
grade inflammation in psychiatric patients that have transformed 
our understanding of neuropsychiatric diseases and urge for 
new diagnostic and therapeutic criteria in the emerging field 
of immuno-psychiatry (100). There are, however, at present, 
insufficient data and reliable concepts on the inflammation 
pathogenesis of MDD to design clinically applicable treatment 
drug protocols with reliable cutoff points for inflammatory 
parameters to guide therapy regimens.
Despite this limitation, a few generalizations can nevertheless 
be made from our study regarding inflammation as a predictor. 
Of the inflammation parameters, the serum CRP and IL-6 
seem to be the most promising parameters for further clinical 
development. They are relatively easy to determine and, thus, 
useful in clinical studies. Using these parameters, a state of 
raised inflammation (as evidenced by raised serum CRP and 
IL-6 levels) characterizes a form of MDD with a relatively poor 
outcome and a non-responsiveness to agents with a predominant 
serotonergic action. Such cases might need a faster step-up to 
drug regimens with agents with dopaminergic (e.g., mirtazapine 
and bupropion) or glutamatergic (e.g., ketamine) effects, 
or a combination of a first-line antidepressant with an anti-
inflammatory agent such as infliximab, minocycline, or fish oil 
(but not aspirin), most of them showing dopaminergic action. 
Varying anti-inflammatory properties of antidepressants as well 
as varying neuro-modulatory effects of anti-inflammatory agents 
(and/or complex interactions thereof) may play a role in the 
therapeutic success or failure of the step-ups.
A word of caution is needed regarding the regimens using 
as add-on the successful anti-inflammatory agents infliximab, 
minocycline, and fish oil: There must indeed be laboratory signs 
of inflammation (i.e., raised serum levels of CRP or IL-6) for this 
addition to be effective. If not, even response rates lower than the 
non-add-on situation might be obtained.
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